31,393 Shares in Neurogene Inc. $NGNE Purchased by Wellington Management Group LLP

Wellington Management Group LLP acquired a new position in Neurogene Inc. (NASDAQ:NGNE) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 31,393 shares of the company’s stock, valued at approximately $987,000.

Several other large investors have also recently added to or reduced their stakes in NGNE. State of Wyoming acquired a new position in shares of Neurogene during the second quarter valued at $31,000. Legal & General Group Plc acquired a new stake in shares of Neurogene during the 2nd quarter valued at $35,000. BNP Paribas Financial Markets raised its position in shares of Neurogene by 89.8% during the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock worth $36,000 after purchasing an additional 978 shares during the period. Daiwa Securities Group Inc. purchased a new stake in shares of Neurogene during the fourth quarter valued at $66,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Neurogene by 17.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock valued at $82,000 after purchasing an additional 1,059 shares during the last quarter. 52.37% of the stock is currently owned by institutional investors and hedge funds.

Neurogene Stock Down 1.8%

NGNE opened at $35.48 on Friday. The firm has a market capitalization of $709.95 million, a P/E ratio of -7.05 and a beta of 1.69. The stock has a fifty day moving average of $36.83 and a 200-day moving average of $29.70. Neurogene Inc. has a 12-month low of $15.93 and a 12-month high of $43.66.

Neurogene (NASDAQ:NGNE) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($1.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.42) by ($0.11). On average, analysts expect that Neurogene Inc. will post -5.62 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. HC Wainwright dropped their price target on Neurogene from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Wednesday, August 12th. Guggenheim upped their price objective on shares of Neurogene from $69.00 to $81.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a report on Friday, July 17th. Canaccord Genuity Group dropped their target price on shares of Neurogene from $180.00 to $166.00 and set a “buy” rating on the stock in a research report on Wednesday, August 12th. Finally, Rodman & Renshaw initiated coverage on shares of Neurogene in a report on Wednesday, June 3rd. They set a “buy” rating and a $70.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $83.67.

Insider Buying and Selling

In other Neurogene news, CFO Christine Cvijic sold 4,200 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $36.13, for a total transaction of $151,746.00. Following the completion of the sale, the chief financial officer directly owned 84,040 shares in the company, valued at approximately $3,036,365.20. This trade represents a 4.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 9,600 shares of company stock worth $339,932. Company insiders own 11.68% of the company’s stock.

About Neurogene

Neurogene, Inc is a clinical?stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno?associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9?based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.